{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0018","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3"},{"groupId":"OG001","value":"51.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"description":"After each dose was administered, patients were asked if they would like to continue rinses with that particular agent. The percentage of patients who expressed an interest in continuing therapy are reported below.","groups":[{"description":"Patients receive (10 mg/mL x 2.5 mL) 25 mg doxepin hydrochloride (diluted to 5 mL with 2.5 mL of sterile water for irrigation, or sterile water for injection, or distilled water) oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.","id":"OG000","title":"Arm I (Doxepin-Placebo)"},{"description":"Patients receive 2.5 mL placebo (diluted to 5 mL with 2.5 mL of sterile water for irrigation, or sterile water for injection, or distilled water) oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm I on day 2.","id":"OG001","title":"Arm II (Placebo-Doxepin)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 9 days","title":"Patient Preference for Continuing Therapy With Oral Doxepin Hydrochloride","type":"SECONDARY","unitOfMeasure":"percentage of patients"}